1. Who are the stakeholders in this case? Which are primary, and which are secondary? What influence do they have?
Stakeholders for GlaxoSmithKline include the following: Employees; stockholders; creditors; suppliers; customers (both prescribing physicians and end users); retailers (domestically and internationally); activist groups (such as the Minnesota Senior Federation, the National Association of the Terminally Ill, the Coalition for Access to Affordable Prescription Drugs, the Massachusetts Senior Action Council, and the American Association for Retired Persons); foreign governments (such as the German Health Ministry and the European Union); federal, state and local governments and regulatory agencies (such as the Food and Drug Administration, Medicare, and the U.S. Congress); the general public; and, the media.
Primary Stakeholders. Primary stakeholders affect the firm's ability to carry out its primary purpose of providing goods and services to society. GSK's primary stakeholders are:
1. Employees;
2. Stockholders;
3. Creditors;
4. Suppliers;
5. Customers;
6. Retailers; and,
7. Health insurance providers.
Employees. Examples of employees include: research scientists, manufacturing personnel, and corporate management. They influence GSK by providing labor, scientific discovery and managerial talents to the firm with an expectation of fair compensation for their efforts.
Stockholders. Examples of stockholders include: institutional investors and private investors. They influence GSK by providing capital to the firm in return for dividends and stock price appreciation.
Creditors. Creditors include banks and other financial institutions. Creditors provide short and long-term loans and are repaid with interest.
Suppliers. Examples of suppliers include chemical companies and packaging companies. These firms provide the inputs for the manufacturing and packaging of the drugs.
Customers. Examples of